<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030519</url>
  </required_header>
  <id_info>
    <org_study_id>intestinal flora study</org_study_id>
    <nct_id>NCT05030519</nct_id>
  </id_info>
  <brief_title>A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer</brief_title>
  <official_title>A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      By measuring the intestinal flora abundance and bacterial count of patients in the early&#xD;
      stage of using pyrotinib to clarify the relationship between diarrhea caused by pyrotinib and&#xD;
      changes in intestinal flora in breast cancer patients, the correlation between the change of&#xD;
      intestinal flora and the relief of diarrhea are also explored after two-cycle treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, small-molecule tyrosine kinase inhibitors (TKI) have achieved good results&#xD;
      in anti-HER2 therapy and have been widely used in clinical practice, such as Breast cancer.&#xD;
      However, such drugs can easily cause diarrhea and disorders of intestinal flora , may affect&#xD;
      the efficacy of the drug and lead to the occurrence of other diseases.This study is to&#xD;
      clarify the connection between the diarrhea caused by pyrotinib and the change of intestinal&#xD;
      flora, pave the way for studying on whether the flora affects the efficacy of the drug and&#xD;
      whether the flora should be supplemented appropriately in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The quantity of intestinal flora from breast cancer patients' fecal microflora at different follow-up nodes</measure>
    <time_frame>January 2021- December 2022</time_frame>
    <description>Fecal samples were collected from patients at each follow-up node to detect the number of bacterial species in the intestinal flora</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The abundance of intestinal flora from breast cancer patients' fecal microflora at different follow-up nodes</measure>
    <time_frame>January 2021- December 2022</time_frame>
    <description>Fecal samples were collected at each follow-up node to detect the richness of different bacterial species in intestinal flora</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate（DCR）</measure>
    <time_frame>January 2021- December 2022</time_frame>
    <description>DCR=CR+PR+SD Complete Remission(CR): All target lesions disappeared, no new lesions appeared, and tumor markers were normal, for at least 4 weeks; Partial Remission(PR): The sum of the maximum diameter of the target lesion is reduced by ≥30% and maintained for at least 4 weeks; Stable Disease(SD): The maximum diameter and reduction of the target lesion did not reach the PR, or the enlargement did not reach the PD;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival（OS）</measure>
    <time_frame>January 2021- December 2022</time_frame>
    <description>Time interval from randomization to death for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>January 2021- December 2022</time_frame>
    <description>Time interval from randomization to first disease progression or death for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>January 2021- December 2022</time_frame>
    <description>ORR=CR+PR Complete Remission(CR): All target lesions disappeared, no new lesions appeared, and tumor markers were normal, for at least 4 weeks; Partial Remission(PR): The sum of the maximum diameter of the target lesion is reduced by ≥30% and maintained for at least 4 weeks;</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>Pyrotinib 400 mg once daily(monotherapy or combined chemotherapy)</description>
    <other_name>Other chemotherapy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Identify the abundance of intestinal flora and the number of bacteria through metagenomic&#xD;
      sequencing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HER2-positive breast cancer at any stage&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female breast cancer patients aged 18-75 years.&#xD;
&#xD;
          2. ECOG performance status of 0 to 1;&#xD;
&#xD;
          3. Known hormone receptor status;&#xD;
&#xD;
          4. HER2 positive breast cance at any stage;&#xD;
&#xD;
          5. breast cancer Patients are about to receive pyrotinib monotherapy or combined&#xD;
             chemotherapy；&#xD;
&#xD;
          6. Patients with adequate organ function before enrollment (no blood transfusion, no&#xD;
             white blood cell or platelet-elevating drugs used within 2 weeks before screening): 1)&#xD;
             Blood routine:ANC≥1.5×10^9/L; PLT≥90×10^9/L; Hb≥90 g/L；2)Blood biochemistry:&#xD;
             TBIL≤1.5×ULN;ALT and AST ≤1.5×ULN; alkaline phosphatase ≤ 2.5×ULN; BUN and&#xD;
             Cr≤1.5×ULN；3) Cardiac color Doppler ultrasound:LVEF≥55%；4) 12-lead ECG: QTcF &lt; 470&#xD;
             msec;&#xD;
&#xD;
          7. Signed the informed consent form prior to patient entry, and have good compliance and&#xD;
             are willing to cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with Severe heart disease or discomfor;&#xD;
&#xD;
          2. Previous or ongoing use of HER2-targeted tyrosine kinase inhibitors ;&#xD;
&#xD;
          3. Inability to swallow, intestinal obstruction, or other factors that affect the taking&#xD;
             and absorption of the drug;&#xD;
&#xD;
          4. Allergy to pyrotinib; history of immunodeficiency, including HIV positive, active&#xD;
             HBV/HCV, other acquired or congenital immunodeficiency disease and organ&#xD;
             transplantation history;&#xD;
&#xD;
          5. Patients during pregnancy or lactation, patients with childbearing potential tested&#xD;
             positive in baseline pregnancy test, or patients unwilling to take effective&#xD;
             contraceptive measures throughout the trial and 7 months after the last study&#xD;
             medication;&#xD;
&#xD;
          6. patients with intestinal disease, serious concomitant diseases, or other comorbid&#xD;
             diseases that will interfere with the planned treatment, or patients not eligible for&#xD;
             this study judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenming Cao, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Breast Medical Oncology, Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenming Cao, Ph.D.</last_name>
    <phone>+86 057188122222</phone>
    <email>caowm@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>China</name>
      <address>
        <city>Zhejiang</city>
        <state>Hangzhou</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenming Cao, Ph.D.</last_name>
      <phone>+86 057188122222</phone>
      <email>caowm@zjcc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Wenming Cao, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ross JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect. 2009 Mar;22(2):93-106. doi: 10.1358/dnp.2009.22.2.1334452. Review.</citation>
    <PMID>19330168</PMID>
  </results_reference>
  <results_reference>
    <citation>Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol. 2009 Aug;87(1):1-11. doi: 10.1016/j.yexmp.2009.05.001. Epub 2009 May 18. Review.</citation>
    <PMID>19450579</PMID>
  </results_reference>
  <results_reference>
    <citation>Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006 Feb 24;124(4):837-48. Review.</citation>
    <PMID>16497592</PMID>
  </results_reference>
  <results_reference>
    <citation>Fernández MF, Reina-Pérez I, Astorga JM, Rodríguez-Carrillo A, Plaza-Díaz J, Fontana L. Breast Cancer and Its Relationship with the Microbiota. Int J Environ Res Public Health. 2018 Aug 14;15(8). pii: E1747. doi: 10.3390/ijerph15081747. Review.</citation>
    <PMID>30110974</PMID>
  </results_reference>
  <results_reference>
    <citation>Parida S, Sharma D. The power of small changes: Comprehensive analyses of microbial dysbiosis in breast cancer. Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):392-405. doi: 10.1016/j.bbcan.2019.04.001. Epub 2019 Apr 11. Review.</citation>
    <PMID>30981803</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang J, Tan Q, Fu Q, Zhou Y, Hu Y, Tang S, Zhou Y, Zhang J, Qiu J, Lv Q. Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications. Breast Cancer. 2017 Mar;24(2):220-228. doi: 10.1007/s12282-016-0734-z. Epub 2016 Oct 5. Review.</citation>
    <PMID>27709424</PMID>
  </results_reference>
  <results_reference>
    <citation>Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006;8(4):R43.</citation>
    <PMID>16859501</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaudet MM, Gierach GL, Carter BD, Luo J, Milne RL, Weiderpass E, Giles GG, Tamimi RM, Eliassen AH, Rosner B, Wolk A, Adami HO, Margolis KL, Gapstur SM, Garcia-Closas M, Brinton LA. Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype. Cancer Res. 2018 Oct 15;78(20):6011-6021. doi: 10.1158/0008-5472.CAN-18-0502. Epub 2018 Sep 5.</citation>
    <PMID>30185547</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA, Spicer D. Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study. Breast Cancer Res Treat. 2020 Jul;182(2):451-463. doi: 10.1007/s10549-020-05702-6. Epub 2020 May 28.</citation>
    <PMID>32468338</PMID>
  </results_reference>
  <results_reference>
    <citation>Goedert JJ, Jones G, Hua X, Xu X, Yu G, Flores R, Falk RT, Gail MH, Shi J, Ravel J, Feigelson HS. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015 Jun 1;107(8). pii: djv147. doi: 10.1093/jnci/djv147. Print 2015 Aug.</citation>
    <PMID>26032724</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

